The Instruction of [2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol

Instruction of [2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol

In the chemical industry, the synthesis of new compounds is an ongoing process that requires the use of various chemical reactions and techniques.
One such compound that has gained attention in recent years is [2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol, which is also known by its chemical name, GSK2891263.

GSK2891263 is a type of molecule known as a quinolizin-2-one derivative, which has been shown to possess antiviral properties against a wide range of viruses including Influenza A and B, respiratory syncytial virus, and herpes simplex virus 1 and 2.
This makes it an important compound in the fight against viral diseases, particularly during the COVID-19 pandemic.

The synthesis of GSK2891263 involves several steps and requires the use of various chemical reagents and techniques.
The following is a step-by-step guide to the synthesis of GSK2891263, which can be used as a reference for chemists and researchers in the field.

Step 1: Synthesis of 2-Methylpropylamine

The synthesis of GSK2891263 begins with the synthesis of 2-methylpropylamine, which is prepared by the reduction of ephedrine using lithium aluminum hydride (LiAlH4).
The resulting 2-methylpropylamine is then salted with a strong acid, such as hydrochloric acid, to form the HCl salt.

Step 2: Synthesis of Ethyl 3-Bromobenzoate

Next, ethyl 3-bromobenzoate is synthesized by the bromination of 3-ethylbenzoic acid using NaN3 as the oxidizing agent.
The resulting ethyl 3-bromobenzoate is then reduced using lithium aluminum hydride (LiAlH4) to form 3-ethyl-2-oxo-2H-chromen-9-one.

Step 3: Synthesis of 2-(2,6-Dimethoxyphenyl)acetamide

The next step involves the synthesis of 2-(2,6-dimethoxyphenyl)acetamide, which is prepared by the reaction of 2,6-dimethoxyphenylamine with acetyl chloride in the presence of a catalyst such as pyridine.
The resulting 2-(2,6-dimethoxyphenyl)acetamide is then hydrolyzed using a strong acid such as hydrochloric acid to form the free amide.

Step 4: Synthesis of [2R-(2a,3b,11bb)]-1,3,4,6,7,11b-Hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo[a]quinolizin-2-ol

The final step in the synthesis of GSK2891263 involves the synthesis of the title compound using a series of chemical reactions.
The synthesis involves the condensation of 2-(2,6-dimethoxyphenyl)acetamide with 1,3-dimethoxy-5-nitrobenzene in the presence of a Lewis acid catalyst, such as aluminum trichloride.
The resulting mixture is then treated with a reducing agent, such as lithium aluminum hydride